Royalty Report: Drugs, HIV / AIDs, Disease – Collection: 243415

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Drugs
  • HIV / AIDs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Cancer
  • Drug Discovery
  • Antibody
  • Vaccine
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 243415

License Grant
Licensor grants the Licensees of Switzerland and the United States, a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Compounds and Products under the Licensor Proprietary Rights and Licensors part of the Joint Patents.
License Property
Licensor has discovered and is developing a series of proprietary compounds which act by binding to the glycoprotein GP 41 of the Human Immunodeficiency virus.

Compound 1 shall mean T-20.
Compound 2 shall mean T-1249, or its Replacement Compound

Licensor discovers and develops novel therapeutic agents that block viral infection by inhibiting viral fusion with host cells.

Field of Use
The Field of Use shall mean the treatment of HIV, a human viral infection.

IPSCIO Record ID: 253

License Grant
Licensor grants Swiss Licensee a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Compounds and Products under the Licensee Proprietary Rights and Licensees’ part of the Joint Patents.
License Property
The Parties have previously entered into (a) a Development and License Agreement (including its Appendices) dated as of the 1st day of July 1999, as amended by the Amendment to the Development and License Agreement (DLA First Amendment) executed July 12, 2004 and rescinded and voided ab initio on July 12, 2004 by the Rescission of the Amendment to the Development and License Agreement (Rescission) and the Letter of Amendment (DLA Second Amendment) effective September 20, 2005.

Product relates to brand name Fuzeon® in indications other than the treatment of HIV.  Fuzeon was developed in collaboration with the Licensee, and is our only currently marketed product.  Fuzeon, which is administered by subcutaneous injection, has been shown to inhibit HIV viral fusion with host cells by blocking the conformational rearrangement of an HIV protein called gp41.  The FDA approved the use of Fuzeon in combination with other anti-HIV drugs for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing anti-HIV therapy.

Date U.S. Pat. No. 5,464,933 11/7/95 Synthetic Peptide Inhibitors of HIV Transmission 6/7/2013
U.S. Patent No. 6,133,418 10/17/00 Synthetic Peptide Inhibitors of HIV Transmission 11/17/2014
U.S. Patent No. 6,475,491 11/5/02 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/7/2015
U.S. Patent No. 6,861,059 3/1/05 Methods and Compositions for Treatment of HIV-1 Infection Using Antiviral Compounds in Simultaneous or Sequential Combinations 9/9/2015
Canadian Patent No. 2,224,008 8/18/09 Treatment of HIV and Other Viral Infections Using Combinatorial Therapy 6/6/2016
U.S. Patent No. 6,281,331 8/28/01 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,015,881 1/18/00 Methods and Compositions for Peptide Synthesis 3/23/2018
U.S. Patent No. 6,824,783 11/30/04 Methods for Inhibition of Membrane Fusion-Associated Events, Including HIV Transmission 11/30/2021

Field of Use
Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, the Licensor's first and only commercial product, Fuzeon (whose generic name is enfuvirtide, originally known as T-20), offers a novel mechanism of action to treat and potentially prevent the transmission of HIV.

IPSCIO Record ID: 1206

License Grant
The Licensor entered into a Development and License Agreement with the Licensee to develop and commercialize T-20, currently marketed as Fuzeon, whose generic name is enfuvirtide, and T-1249, or a replacement compound.

The Development and License Agreement has been amended several times; most recently in March 2007, the Agreement was amended to cover only the development and commercialization of Fuzeon.

License Property
The returned intellectual property covers both research and development stage molecules, including T-1249.

The Licensor is a biopharmaceutical company primarily engaged in the commercialization of a new class of antiviral drug treatments called fusion inhibitors. Fusion inhibitors prevent viral fusion, a complex process by which viruses attach to, penetrate and infect host cells. If a virus cannot enter a host cell, the virus cannot replicate. By inhibiting the fusion process of particular types of viruses, like the Human Immunodeficiency Virus, our first commercial product and our development-stage compound offer a novel mechanism of action to treat and potentially prevent the transmission of HIV.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 289819

License Grant
Licensor hereby grants to Licensee an exclusive royalty-bearing license (or sublicense, as the case may be), under the Licensor Patents, the Licensor  Know-How and the Inventions (if any) solely to Commercialize, use, have used, offer for sale and sell Licensed Products in the Field in the Territory.

With this agreement, Licensor will maintain responsibility for the development and FDA approval of leronlimab for all HIV-related and other indications, while Licensee has been granted an exclusive license to market and distribute leronlimab.

License Property
Leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

Licensor has developed leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is pursuing the clinical development of its PRO 140 drug candidate for the treatment of multi-drug resistant Human Immunodeficiency Virus (“HIV”) infection, as well as related HIV infection indications.

Field of Use
The field of use is for the treatment of HIV.

IPSCIO Record ID: 203504

License Grant
Licensor grants an exclusive (even as to  Licensor), license under the Patent Assets and Know-How, including the right to grant sublicenses, to develop, make, have made, use, import, offer for sale, market and sell and otherwise dispose of Compound and Product, including any Improvements thereto, in the Territory.
License Property
The Licensed products contain the compound.  The Compound shall mean a condensation polymer of an aromatic sulfonic acid and an aldehyde or a pharmaceutically acceptable salt or prodrug thereof or a derivative, homolog, or analog thereof.
Field of Use
The Compound is for a candidate topical microbicide used to prevent infection by the human immunodeficiency virus (HIV) and other sexually transmitted pathogens.

IPSCIO Record ID: 362454

License Grant
Pursuant to the terms of a certain License Agreement, by and between a University, the Licensors Designee in this agreement, and Licensor, the University and Licensor have agreed to grant Licensee a sublicense in certain inventions relating to ß-L-FD4C.

Licensor hereby grants to Licensee a non-transferable, worldwide, exclusive license under the Licensed Technology to make, have made, import, export, use, sell and have sold Licensed Products and practice the Inventions.

License Property
The University has licensed to Licensor certain inventions relating to, among other things, potential anti-viral compounds, including ß-L-FD4C.

The patents include
Novel L-23-Dideoxy Nucleoside Analogs as Anti-Hepatitis (HBV) Agents;
Reduced Toxicity Compositions and Methods for Treating HIV Infections; and,
Process for High Yield Diastereoselective Syntheses of Dideoxvnucleotides.

Field of Use
The field of use includes HIV treatments.

IPSCIO Record ID: 362516

License Grant
The University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 365329

License Grant
This amendment, included with this agreement, updates the financial terms, including the royalty rates.

By the original agreement, University grants to an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use, import, sell and offer for sale University Licensed Products.

This license grant is exclusive with respect to Universitys rights, except that University may use and permit other nonprofit organizations to use the University Patent Rights for educational and research purposes and not for sale or offer of sale.

License Property
The University controls certain intellectual property developed related to pathogenic viral proteins which control host cell functions.
Field of Use
Licensee is a biopharmaceutical company engaged in the discovery and development of drugs and DNA vaccines for the treatment of infectious diseases, including the HIV and hepatitis C viruses, as well as cancer and inflammatory diseases.

IPSCIO Record ID: 322463

License Grant
Licensor sold Leronlimab to Licensee where Licensee is responsible for all development, manufacturing and commercialization efforts.
License Property
Leronlimab (PRO 140) is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases including certain liver diseases.

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control.  Blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Field of Use
The field of use is for the treatment in HIV infection, tumor metastases, and other diseases including certain liver diseases.

HIV (human immunodeficiency virus) is a virus that attacks cells that help the body fight infection.
Metastasis means that cancer spreads to a different body part from where it started.
Liver cancer is the growth and spread of unhealthy cells in the liver.

Licensee is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.

IPSCIO Record ID: 26363

License Grant
The Company entered into a worldwide exclusive patent license agreement with the Licensor, government public health organization, concerning composition of matter for BlockAide/CR.
License Property
BlockAide/CR&#-3884; is a peptide-based drug that is intended to work by blocking viral entry and infection of human immune system cells.

The patents covering a peptide product, known as BlockAide, for the treatment and prevention of HIV.

Field of Use
The rights granted apply to the medical industry relating to human infections.

IPSCIO Record ID: 243414

License Grant
Licensor grants an exclusive license under the Technology and Patents to make, have made, import, use, offer for sale, and sell Licensed Product for use in the Field.  The license granted shall include the right to grant a sublicense to one Sublicensee in each country.
License Property
Licensor owns certain patent rights and technology relating to Anti-CD4 Monoclonal Antibodies.
Field of Use
The field shall mean the manufacture, use, importation, offer for sale or sale of Licensed Product for human use only, including therapeutic, prophylactic and diagnostic use.

5A8 is a humanized anti-CD4 monoclonal antibody that is in preclinical development for treatment of human immunodeficiency virus, or HIV. The virus enters the host cell by binding to the CD4 receptors on these cells. In lab studies, our 5A8 antibody binds to the CD4 receptor on the cell surface and prevents viral entry into the cell, thereby blocking infection.

IPSCIO Record ID: 289184

License Grant
The University Foundation grants to Licensee the exclusive right and license to make, have made, use, import, offer for sale, and sell in the Territory, Licensed Products during the term of this Agreement including Licensee’s right to grant sublicenses.

The license granted is subject to a reserved, non-exclusive license of Foundation, transferable to University and its not-for-profit academic collaborators, to practice the Licensed Patents in the Field, only for the purpose of non-commercial scientific inquiry, academic research, and education.

License Property
Licensed Product means any compound, product, service, or process in the Field, the manufacture, use, or sale of which, but for the license granted herein, would infringe at least one Valid Claim.

Licensed Patents means (i) the patent applications listed, (ii) the United States patents that may issue from the patent applications listed and from divisionals and continuations and continuations-in-part of such United States patents and patent applications, (iii) all foreign counterparts of such patent applications, and all patents that issue thereon anywhere in the world, including reexamined and reissued patents. Licensed Patents shall also mean any patent application having claims in the Field directed to an invention made in the laboratory of Dr. Vasu Nair six months or less prior to the Effective date, and (iv) with respect to the matters described in clauses (i), (ii) and (iii) above, all provisionals, renewals, re-examinations, patents of addition, supplementary protection certificates, extensions, restorations of patent terms, letters of patent, registration or confirmation patents and reissues of such patents or patent applications.

7,250,421 – Diketo acids with nucleobase scaffolds anti-HIV replication inhibitors targeted at HIV integrase

Indication shall mean the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with a specific virus in the Field. For example HIV Indication means the prevention, treatment or diagnosis of a condition, infection or disease caused by or associated with Human Immunodeficiency Virus (HIV) and HCV Indication means prevention, treatment or diagnosis of a condition, infection or a disease caused by or associated with Hepatitis C Virus (HCV).

Field of Use
Field means any and all anti-viral uses, including but not limited to prophylaxis, diagnosis or treatment of a condition, infection or disease associated with a virus, except the Field specifically excludes any anti-viral use associated with (a) the following DNA virus families  poxviridae, polyomaviridae, papillomaviridae, adenoviridae, and parvoviridae; and (b) all RNA viruses except for the following RNA virus families, which are specifically included in the Field  retroviridiae (for example HIV as defined below), flaviviridae (for example HCV as defined below), orthomyxoviridae, paramyxoviridae, and coronaviridae. In the event that Licensee terminates the Sponsored Research Agreement (“SRA”), a copy of which is attached as Appendix J, pursuant to paragraph 16(d) of the SRA, the Field of this License Agreement shall automatically be amended to exclude HCV.

IPSCIO Record ID: 362455

License Grant
The University grants an exclusive, worldwide, right and license under the University Subject Technology to develop, make, have made, use, market, import, have imported, Sell, offer for Sale and have Sold any and all Licensed Products in the field and in the Territory.
License Property
The University owns certain intellectual property relating to the treatment of Human Immunodeficiency Virus (HIV) and Hepatitis B Virus (HBV).

Licensed Products means a product containing P-VL-FD4C that is developed, made, used, marketed, imported, Sold, or offered for Sale by Licensee, its Affiliates or any Sublicensees in any country of the Territory where the University owns or controls at least one Valid Claim covering the Subject Technology.

University Subject Technology shall mean all technology, trade secrets, know-how, methods of treatment, documents, materials, tests, all improvements thereto, and all proprietary information pertaining to the compound B-L-FD4C (2 ,3-dideoxy-2 ,3 -didehydro-B-L-5-fluorocytidine) or any 5- or N4 derivatives or products thereof.

Field of Use
Field means all human prophylactic and therapeutic applications with respect to HIV and HBV.

IPSCIO Record ID: 279299

License Grant
This agreement is to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

For the License of proprietary rights,  Licensor grants a co-exclusive, with Licensor, worldwide right and license, without the right to sublicense, within the Territory, to use the Licensor Intellectual Property and Licensor Patent Rights and the Program Intellectual Property owned by Licensor, in each case with application to the Field to the extent necessary or useful to research, develop, have developed, make, have made, use, distribute, promote, market, offer for sale, sell, have sold, import and export Designated Shared Compounds, Derivative Compounds thereof, Shared Products and, to the extent permitted Independent Compounds, Derivative Compounds thereof and Independent Products.

The research license portion is non-exclusive.

License Property
ALIS means the Automated Ligand Identification System, an automated, ultra-high throughput ligand selection system proprietary to Licensor that is used to identify multiple classes of chemical ligands against a target protein.

Licensor will screen at least five million (5,000,000) compounds contained in the Licensor NeoMorph Screening Library against each Shared Target.

Licensee will provide at least two hundred fifty (250) nmol. of each of the purified functionally-active Shared Target proteins.

Derivative Compounds means any analogs, homologs or isomers of a Designated Shared Compound and/or an Independent Compound, as applicable.

Field of Use
Field means all preventative, therapeutic and diagnostic uses of Shared Products or Independent Products with respect to human immunodeficiency virus (HIV) in humans.

Licensee is interested in identifying potential pharmaceutical products for the treatment of human immunodeficiency virus (HIV) and wishes to identify compounds that exhibit a high degree of chemical binding and functional activity to specific protein targets involved in HIV.

IPSCIO Record ID: 243454

License Grant
Pursuant to this agreement, Licensee shall solely own all marketing rights to Products, including, not limited to, the exclusive, worldwide, transferable rights to market, sell, have sold, import, export and distribute solely Products.

Licensor will provide all Compounds to Licensee on an exclusive basis, and Licensor is expressly prohibited from providing any and all such Compounds to a Third Party as part of the Licensor Library, without the prior written consent of Licensee.

Licensor grants a nonexclusive, worldwide, transferable and sublicensable right and license to Licensor Technology to the extent that it is necessary for Licensee, to develop, make, have made, use, import, export, offer for sale, have sold and sell Development Compound(s) and/or Product(s).

And, for the research, Licensor grants a worldwide, non-exclusive, non-transferable, non-sublicensable, right and license under the Licensor Technology solely to conduct activities assigned to Licensee under the Research Plan during the term of the Research Collaboration.

License Property
Product shall mean any human diagnostic, human therapeutic and/or human prophylactic product for use within the Field and incorporating a Compound.

Compound shall mean any one or more chemical entity(ies) that is specifically designed by Licensee and/or Licensor in the course of performing or in connection with the Research Plan; or designed by Licensee and/or Licensor, and synthesized by Licensor, in the course of performing or in connection with the Research Plan; or synthesized by Licensor in the course of performing or in connection with the Research Plan; or has been designated as a Development Compound.

LC-MS/ELSD shall mean liquid chromatography mass spectrometry with evaporative light scattering detector.

“Target(s)” shall mean any one or more of (a) the HIV gp120 glycoprotein, including all genetic variants of such glycoprotein, or (b) the HIV gp41 glycoprotein, including all genetic variants of such glycoprotein.

Under the terms of the agreement, the Companies will work to identify small molecule inhibitor compounds against two HIV entry targets, gp41 and gp120. The Companies will collaborate to identify orally active lead compounds and then optimize preclinical candidates.

Field of Use
Field shall mean the discovery, development and commercialization of small chemical molecules for the diagnosis of, or the therapeutic and/or prophylactic treatment of all human conditions and/or diseases.

Collaborative agreement relates to discover and develop small molecule entry inhibitors of the human immunodeficiency virus (HIV).

IPSCIO Record ID: 243453

License Grant
Pursuant to a previous agreement, the parties entered into a collaboration for the worldwide development and marketing of a Product 1 and a Product 2 as drugs for the treatment of HIV infection from among proprietary compounds of Licensor.

Licensor grants a worldwide, sole and exclusive right and license, with the right to sublicense, to make and have made, use, offer for sale, import and sell Drug Candidates and Joint Products under Licensors part of the Joint Research Patents and any rights licensed by Licensor to Licensee in the License Agreement which also cover such Drug Candidate or Joint Products.

Licensee shall have the right to sublicense the rights granted in the Field to any third party.

License Property
Type I Drug Candidate shall mean any Peptide which is covered by the Licensors Patents and had been identified by Licensor prior to July 1, 1999 and are listed in Licensors Peptide Database.

Type II Drug Candidate shall mean any Peptide which is covered by the Licensors Patents and is identified by Licensor or Licensee after July 1, 1999.

'Peptide' shall mean a peptide, peptoid, or peptidomimetic of molecular weight greater than 2000 Daltons.

Field of Use
Field shall mean Peptides for use in the treatment of HIV infection which inhibit fusion by interaction with HIV gp41.

IPSCIO Record ID: 178198

License Grant
U.S. Licensor and Owner in Ireland hereby jointly grant to Licensee the exclusive world rights to all present and future Patent Rights, Know-How and the Background Technology for all uses thereunder with the right to sublicense, to make, have made, use and sell the Products and Combination Products, and to practice, modifyand improve the Licensed Processes within the Field of Activity, in the Territory, and to sublicense others to do the same, all as herein provided.
License Property
Licensor has been assigned Owners rights in the Patent Rights and Know-How relating to the treatment of human/animal immunodeficiency as disclosed in U.S. Patent No. 4,956,355 entitled Agents for the Arrest and Therapy of Retrieval Infections, the said assignment allows Licensor sufficient portion of rights to grant licenses to make, use, exercise and vend the Products and Licensed Processes and Licensor has been granted an Investigational New Drug (IND) status from the U.S. Food and Drug Authority for the use of the technology outlined in the U.S. Patent No. 4,956,355 in the treatment of HIV infection, IND No. 31,980.

ANTI-VIRAL FORMULATION OF DEHYDROEPIANDROSTERONE (DHEA)'s s anti-retroviral effectiveness was shown through experiments which demonstrated in tissue culture that DHEA inhibited HIV replication.

Field of Use
This agreement has application in the medical and pharmaceutical and veterinary industries.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.